ABIO ARCA biopharma Inc

Price (delayed)

$3.485

Market cap

$50.56M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.42

Enterprise value

$14.65M

ARCA biopharma is dedicated to developing genetically targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. ARCA's lead product candidate, GencaroTM(bucindolol hydrochloride), is an investigational, pharmacologically ...

Highlights
The company's debt has shrunk by 100% QoQ and by 100% YoY
ARCA biopharma's net income has increased by 25% YoY but it has decreased by 12% QoQ
ARCA biopharma's EPS has increased by 24% YoY but it has decreased by 14% from the previous quarter
The company's quick ratio has shrunk by 61% QoQ and by 30% YoY
The company's equity fell by 13% YoY and by 5% QoQ

Key stats

What are the main financial stats of ABIO
Market
Shares outstanding
14.51M
Market cap
$50.56M
Enterprise value
$14.65M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.44
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$6M
EBITDA
-$5.9M
Free cash flow
-$4.95M
Per share
EPS
-$0.42
Free cash flow per share
-$0.34
Book value per share
$2.42
Revenue per share
$0
TBVPS
$2.53
Balance sheet
Total assets
$36.71M
Total liabilities
$1.58M
Debt
$0
Equity
$35.13M
Working capital
$35.09M
Liquidity
Debt to equity
0
Current ratio
23.19
Quick ratio
22.71
Net debt/EBITDA
6.08
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-15.5%
Return on equity
-16.1%
Return on invested capital
N/A
Return on capital employed
-17.1%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ABIO stock price

How has the ARCA biopharma stock price performed over time
Intraday
4.03%
1 week
0.14%
1 month
6.57%
1 year
72.52%
YTD
105%
QTD
-9.01%

Financial performance

How have ARCA biopharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$7.98M
Net income
-$6M
Gross margin
N/A
Net margin
N/A
ARCA biopharma's net income has increased by 25% YoY but it has decreased by 12% QoQ
ABIO's operating income is up by 12% year-on-year but it is down by 9% since the previous quarter

Growth

What is ARCA biopharma's growth rate over time

Valuation

What is ARCA biopharma stock price valuation
P/E
N/A
P/B
1.44
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
ARCA biopharma's EPS has increased by 24% YoY but it has decreased by 14% from the previous quarter
ABIO's price to book (P/B) is 97% higher than its last 4 quarters average of 0.7 and 73% higher than its 5-year quarterly average of 0.8
The company's equity fell by 13% YoY and by 5% QoQ

Efficiency

How efficient is ARCA biopharma business performance
ARCA biopharma's return on assets has decreased by 17% QoQ but it has increased by 14% YoY
The return on equity has declined by 17% since the previous quarter but it has grown by 14% year-on-year

Dividends

What is ABIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ABIO.

Financial health

How did ARCA biopharma financials performed over time
ARCA biopharma's total liabilities has surged by 88% QoQ and by 3.5% YoY
The company's quick ratio has shrunk by 61% QoQ and by 30% YoY
The company's debt is 100% lower than its equity
The company's debt to equity has shrunk by 100% QoQ and by 100% YoY
The company's debt has shrunk by 100% QoQ and by 100% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.